Quantcast

Latest Hairy cell leukemia Stories

2014-07-01 08:29:55

Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer THOUSAND OAKS, Calif., July 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational bispecific T cell engager (BiTE(®)) antibody blinatumomab, for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly...

2014-04-21 12:27:29

SUNNYVALE, Calif., April 21, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that data from the Phase III PCYC-1112 (RESONATE(TM)) study of single agent IMBRUVICA(TM) (ibrutinib) vs. ofatumumab, an established therapy in relapsed refractory CLL, as well as data from an Independent Efficacy Evaluation of IMBRUVICA after three years of follow-up, will be presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting in Chicago, Illinois May 30 - June...

2014-01-16 14:22:49

University of Leicester researchers deploy 'precision medicine' to successfully target advanced form of leukaemia with skin cancer drug A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer. The research, which is published today (Thursday 16 January) in the New England Journal of Medicine, indicates Vemurafenib, a BRAF inhibitor that has been...

2013-02-11 15:45:20

Discovering what they call the "Achilles' heel" for lymphoid leukemia, an international research team has tested a possible alternative treatment that eradicated the disease in mouse models. Reporting their results Feb. 11 in the journal Cancer Cell, the scientists said the targeted molecular therapy described in their study could have direct implications for current treatment of Acute Lymphoid Leukemia (ALL) in people. Led by researchers at Cincinnati Children's Hospital Medical Center...

2012-12-11 12:25:41

Ibrutinib, rituximab deliver a 1-2 punch to patients with few good options A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center. Researchers presented the results today at the 54th annual meeting of the American Society of Hematology (ASH). "This is a patient population with a great...

2012-12-10 15:16:13

Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About...

2012-07-23 06:17:28

(Ivanhoe Newswire) - Each year an estimated 70,000 people globally are diagnosed with the kidney immune disorder, idiopathic membranous nephropathy (IMN). Idiopathic membranous nephropathy (IMN) can eventually lead to kidney failure. Standard therapies for IMN can be toxic and lead to further complications, but a new study has discovered the drug rituximab which is commonly used to treat lymphoma and arthritis also benefits patients with IMN. Standard therapy for IMN includes...

2012-07-20 12:07:36

Rituximab is more effective and less toxic than standard therapies Highlights: Patients with a particular kidney immune disorder experienced remission when taking the immune drug rituximab, even when standard therapies had failed. Rituximab was safe and well-tolerated by all patients in the study. Each year, an estimated 70,000 people globally are diagnosed with the disorder, called idiopathic membranous nephropathy. A drug commonly used to treat immune disorders such as lymphoma...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related